ソース:[1] J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned? (https://finance.yahoo.com/news/j-j-vs-abbvie- ...)[2] J&J flexes $15B quarter for innovative drugs as biosimilars chip away at Stelara | Fierce Pharma (https://www.fiercepharma.com/pharma/jj-flexes ...)[3] AbbVie (ABBV) Extends Rinvoq's Patent Protection, Boosting Stock - GuruFocus (https://vertexaisearch.cloud.google.com/groun ...)